# CC-99282 + Rituximab Early Post CART for Non-Hodgkin's Lymphoma

> **NCT06209619** · PHASE1 · RECRUITING · sponsor: **Nathan Denlinger** · enrollment: 18 (estimated)

## Conditions studied

- B-Cell Non-Hodgkin Lymphoma-Recurrent
- Diffuse Large B-Cell Lymphoma-Recurrent
- Follicular Lymphoma-Recurrent
- High Grade B-Cell Lymphoma-Recurrent
- Primary Mediastinal Large B-Cell Lymphoma-Recurrent
- Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma-Recurrent
- B-Cell Non-Hodgkin Lymphoma-Refractory
- Diffuse Large B-Cell Lymphoma-Refractory
- Follicular Lymphoma-Refractory
- High Grade B-Cell Lymphoma-Refractory
- Primary Mediastinal Large B-Cell Lymphoma-Refractory
- Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma-Refractory

## Interventions

- **PROCEDURE:** Biopsy
- **PROCEDURE:** Biospecimen Collection
- **PROCEDURE:** Computed Tomography
- **DRUG:** Golcadomide
- **PROCEDURE:** Positron Emission Tomography
- **BIOLOGICAL:** Rituximab

## Key facts

- **NCT ID:** NCT06209619
- **Lead sponsor:** Nathan Denlinger
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-01-29
- **Primary completion:** 2026-12-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2026-02-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06209619

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06209619, "CC-99282 + Rituximab Early Post CART for Non-Hodgkin's Lymphoma". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06209619. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*